NO20081365L - Ny krystallinsk form av et pyridazino[4,5-b]indolderivat - Google Patents

Ny krystallinsk form av et pyridazino[4,5-b]indolderivat

Info

Publication number
NO20081365L
NO20081365L NO20081365A NO20081365A NO20081365L NO 20081365 L NO20081365 L NO 20081365L NO 20081365 A NO20081365 A NO 20081365A NO 20081365 A NO20081365 A NO 20081365A NO 20081365 L NO20081365 L NO 20081365L
Authority
NO
Norway
Prior art keywords
pyridazino
crystalline form
new crystalline
indole derivative
indole
Prior art date
Application number
NO20081365A
Other languages
English (en)
Norwegian (no)
Inventor
John D Higgins
William L Rocco
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37546937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081365(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of NO20081365L publication Critical patent/NO20081365L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20081365A 2005-08-29 2008-03-14 Ny krystallinsk form av et pyridazino[4,5-b]indolderivat NO20081365L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71215305P 2005-08-29 2005-08-29
PCT/US2006/033254 WO2007027525A1 (fr) 2005-08-29 2006-08-24 Nouvelle forme cristalline d'un derive de pyridazino [4,5-b]indole

Publications (1)

Publication Number Publication Date
NO20081365L true NO20081365L (no) 2008-04-03

Family

ID=37546937

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081365A NO20081365L (no) 2005-08-29 2008-03-14 Ny krystallinsk form av et pyridazino[4,5-b]indolderivat

Country Status (32)

Country Link
US (1) US7683062B2 (fr)
EP (1) EP1924585B1 (fr)
JP (1) JP5063600B2 (fr)
KR (2) KR20130087059A (fr)
CN (1) CN101253176B (fr)
AR (1) AR057099A1 (fr)
AT (1) ATE531717T1 (fr)
AU (1) AU2006285142B2 (fr)
BR (1) BRPI0615259A2 (fr)
CA (1) CA2619284C (fr)
CR (1) CR9723A (fr)
CY (1) CY1112317T1 (fr)
DK (1) DK1924585T3 (fr)
EA (1) EA014164B1 (fr)
EC (1) ECSP088209A (fr)
ES (1) ES2375841T3 (fr)
HK (1) HK1123794A1 (fr)
HR (1) HRP20120073T1 (fr)
IL (1) IL189276A (fr)
MA (1) MA30000B1 (fr)
NO (1) NO20081365L (fr)
NZ (1) NZ566087A (fr)
PL (1) PL1924585T3 (fr)
PT (1) PT1924585E (fr)
RS (1) RS52318B (fr)
SI (1) SI1924585T1 (fr)
TN (1) TNSN08059A1 (fr)
TW (1) TW200813060A (fr)
UA (1) UA91716C2 (fr)
UY (1) UY29771A1 (fr)
WO (1) WO2007027525A1 (fr)
ZA (1) ZA200801890B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2545968C (fr) * 2003-11-17 2010-03-09 Merck Eprova Ag Formes cristallines de dihydrochlorure de (6r)-l-erythro-tetrahydrobiopterine
ES2370829T3 (es) * 2004-06-02 2011-12-23 Sandoz Ag Producto intermedio de meropenem en forma cristalina.
AU2006298881A1 (en) * 2005-09-21 2007-04-12 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
WO2007053427A2 (fr) * 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Nouveaux procédés de synthèse de dérivés de benzamide de type pipérazinyle et diazapanyle
EA016054B1 (ru) * 2006-06-16 2012-01-30 Х. Лундбекк А/С Кристаллические формы 4-[2-(4-метилфенилсульфанил)фенил] пиперидина с объединенным ингибированием повторного поглощения серотонина и норадреналина для лечения невропатической боли
ES2442257T3 (es) * 2006-10-27 2014-02-10 Signal Pharmaceuticals Llc Formas sólidas que comprenden 4-[9-(tetrahidro-furan-3-il)-8-(2,4,6-trifluoro-fenilamino)-9H-purin-2-ilamino]-ciclohexan-1-ol, sus composiciones y sus usos
EP2085397A1 (fr) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Forme cristalline d'abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
AU2009283039A1 (en) * 2008-08-18 2010-02-25 Sanofi-Aventis U.S. Llc Process for preparing polymorph of 7-chloro-N, N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydr0-4H-pyridazin0[4,5-b]indole-1-acetamide
KR101512548B1 (ko) 2010-03-12 2015-04-15 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
WO2012030957A2 (fr) * 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Sels non hygroscopiques d'agonistes de 5-ht2c
WO2013044816A1 (fr) * 2011-09-30 2013-04-04 Sunshine Lake Pharma Co., Ltd. Formes cristalline d'azilsartan et leur préparation et leurs utilisations
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
JP2018513153A (ja) 2015-04-24 2018-05-24 オメロス コーポレーション Ｐｄｅ１０インヒビターならびに関連する組成物および方法
WO2017079678A1 (fr) 2015-11-04 2017-05-11 Omeros Corporation Formes solides d'un inhibiteur de pde10
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766823B1 (fr) 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
FR2829939B3 (fr) 2001-09-21 2003-11-28 Sanofi Synthelabo Utilisation du 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5- dihydro-4h-pyridazino(4,5-b)indole-1-acetamide pour la preparation de medicaments destines au traitement de la polyarthrite rhumatoide
US20050220881A1 (en) 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition

Also Published As

Publication number Publication date
CN101253176A (zh) 2008-08-27
JP5063600B2 (ja) 2012-10-31
PL1924585T3 (pl) 2012-08-31
US20080139569A1 (en) 2008-06-12
PT1924585E (pt) 2012-01-19
CN101253176B (zh) 2012-04-18
RS52318B (en) 2012-12-31
AU2006285142B2 (en) 2012-06-14
ES2375841T3 (es) 2012-03-06
EP1924585B1 (fr) 2011-11-02
DK1924585T3 (da) 2012-02-27
CY1112317T1 (el) 2015-12-09
JP2009506116A (ja) 2009-02-12
UA91716C2 (ru) 2010-08-25
KR20130087059A (ko) 2013-08-05
AU2006285142A1 (en) 2007-03-08
AR057099A1 (es) 2007-11-14
ZA200801890B (en) 2009-11-25
NZ566087A (en) 2011-03-31
SI1924585T1 (sl) 2012-09-28
UY29771A1 (es) 2007-03-30
EP1924585A1 (fr) 2008-05-28
CR9723A (es) 2008-06-18
US7683062B2 (en) 2010-03-23
EA200800716A1 (ru) 2008-08-29
CA2619284C (fr) 2014-04-29
BRPI0615259A2 (pt) 2011-05-17
IL189276A0 (en) 2008-08-07
TNSN08059A1 (en) 2009-07-14
MA30000B1 (fr) 2008-12-01
ECSP088209A (es) 2008-06-30
TW200813060A (en) 2008-03-16
CA2619284A1 (fr) 2007-03-08
HRP20120073T1 (hr) 2012-07-31
WO2007027525A1 (fr) 2007-03-08
KR20080050577A (ko) 2008-06-09
ATE531717T1 (de) 2011-11-15
HK1123794A1 (en) 2009-06-26
EA014164B1 (ru) 2010-10-29
IL189276A (en) 2012-07-31

Similar Documents

Publication Publication Date Title
NO20081365L (no) Ny krystallinsk form av et pyridazino[4,5-b]indolderivat
NO20072689L (no) Tetrasykliske indolderivater som antivirale midler
UA93043C2 (ru) ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ ДЛЯ ПОЛУЧЕНИЯ ТРАНС-5-ХЛОР-2-МЕТИЛ-2,3,3А,12В-ТЕТРАГИДРО-1Н-ДИБЕНЗ[2,3:6,7]ОКСЕПИНО[4,5-с]ПИРОЛА
NO2013017I1 (no) (a)dekstrometorfan eller et farmasøytisk akseptabelt salt, en forløper eller derivat, for eksempel ekstrometorfanhydrobromid og spesielt dekstrometorfanhydrobromid monohydrat; og (b) quinidin eller etfarmasøytisk akseptabelt salt, en forløper eller derivat derav, for eksempel quinidin og spesielt quinidinsulfat dihydrat
WO2004056827A3 (fr) Derives de pyrrolo-pyrazoles substitues constituant des inhibiteurs de kinases
CY1111767T1 (el) Υδρογονωμενα παραγωγα βενζο[c]θειοφαινιου ως ανοσορρυθμιστες
WO2002050061A8 (fr) Derives de la piperazine utilises pour le traitement d'infections bacteriennes
ECSP10010197A (es) Derivados de piridina y pirazina útiles en el tratamiento de trastornos de proliferación celular
NO20092585L (no) Forbindelser og farmasoytiske sammensetninger for behandling av virale infeksjoner
NO2012006I2 (no) Telaprevir og enhver terapeutisk ekvivalent form derav som er beskyttet av basispatentet, slik som farmasøytisk akseptable salter og/eller solvater av telaprevir eller solvater av slike salter
CY1106606T1 (el) Διϋδροξυπυριμιδινο καρβοξαμιδια αναστολεις της ιντεγκρασης του hiv
UY28013A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
NO20044974L (no) Imidazo [1,2-a]pyrazin-8-ylaminer, fremgangsmater for fremstilling og anvendelse derav
WO2002009650A3 (fr) Compositions et procedes destines a la reparation et/ou la regeneration d'un myocarde endommage
NO20043038L (no) Polymorfe former av klopidogrel-hydrogensulfat
ECSP055844A (es) Nuevos compuestos triciclicos
NO20056178L (no) CCI-779 lyofiliserte formuleringer
NO20044501L (no) [1,4] diazenino [6,7,1-IJ] kinolin-derivater som antipsykotis og antifedme-midler
CY1108246T1 (el) ΠΑΡΑΓΩΓΑ 1Η-ΘΕΙΕΝΟ[2,3-c] ΠΥΡΑΖΟΛΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΗΣ
WO2002013760A3 (fr) Procedes et compositions permettant la reparation et/ou la regeneration de myocarde endommage
MXPA06000418A (es) Derivados de ariltiourea sustituida utiles como inhibidores de duplicacion viral.
WO2006052886A8 (fr) Metabolites de certains derives de [1,4]diazepino[6,7,1-ij] quinoline et procedes de preparation et d'utilisation de ceux-ci
NO20080110L (no) Benzimidazolderivativer som 5-HT6,5-HT24
DK2185561T3 (da) Derivater af 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6-carboxamid og 2,3,4,5-tetrahydroprrolo(1,2-a)-diazepin-7-carboxamid, fremstilling deraf og terapeutisk anvendelse deraf
IL195837A0 (en) 4-amino-3-arylamino-6-arylpyrazolo[3,4-d]

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application